[A24-111] Pembrolizumab (endometrial carcinoma) – Benefit assessment according to §35a Social Code Book V
Last updated 17.02.2025
Project no.:
A24-111
Commission:
Commission awarded on 14.11.2024 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
First-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma
Result of dossier assessment:
- Patients with mismatch repair deficiency or high-frequency microsatellite instability who are candidates for systemic therapy: added benefit not proven
- Patients with mismatch repair proficiency who are candidates for systemic therapy: added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://doi.org/10.60584/A24-111